Protein kinase Ca (PKCa) can phosphorylate the epidermal growth factor receptor (EGFR) at threonine 654 (T654) to inhibit EGFR tyrosine phosphorylation (pY-EGFR) and the associated activation of downstream effectors. However, upregulation of PKCa in a large variety of cancers is not associated with EGFR inactivation, and factors determining the potential of PKCa to downregulate EGFR are yet unknown. Here, we show that ectopic expression of annexin A6 (AnxA6), a member of the Ca 2 þ and phospholipidbinding annexins, strongly reduces pY-EGFR levels while augmenting EGFR T654 phosphorylation in EGFR overexpressing A431, head and neck and breast cancer cell lines. Reduced EGFR activation in AnxA6 expressing A431 cells is associated with reduced EGFR internalization and degradation. RNA interference (RNAi)-mediated PKCa knockdown in AnxA6 expressing A431 cells reduces T654-EGFR phosphorylation, but restores EGFR tyrosine phosphorylation, clonogenic growth and EGFR degradation. These findings correlate with AnxA6 interacting with EGFR, and elevated AnxA6 levels promoting PKCa membrane association and interaction with EGFR. Stable expression of the cytosolic N-terminal mutant AnxA6 1-175 , which cannot promote PKCa membrane recruitment, does not increase T654-EGFR phosphorylation or the association of PKCa with EGFR. AnxA6 overexpression does not inhibit tyrosine phosphorylation of the T654A EGFR mutant, which cannot be phosphorylated by PKCa. Most strikingly, stable plasma membrane anchoring of AnxA6 is sufficient to recruit PKCa even in the absence of EGF or Ca 2 þ . In summary, AnxA6 is a new PKCa scaffold to promote PKCa-mediated EGFR inactivation through increased membrane targeting of PKCa and EGFR/PKCa complex formation.
INTRODUCTION
Overexpression or mutation of the epidermal growth factor receptor (EGFR, ErbB1) is common in breast, head and neck, and other cancers, leading to aberrant activation of effector pathways and cell transformation. 1 At the cell surface, ligand binding results in EGFR dimerization and activation of its tyrosine kinase (TK) domain. This triggers EGFR tyrosine autophosphorylation and binding of adapters, which link EGFR to downstream effectors that regulate proliferation and differentiation. 2, 3 To avoid constitutive signaling, ligand binding also initiates rapid EGFR internalization and lysosomal degradation. 2, 4, 5 Alternatively, heterologous desensitization of EGFR can occur through the protein kinase C (PKC) family of serine/threonine kinases activated by G-protein coupled receptors, platelet-derived growth factor, hormone-induced phosphatidylinositol turnover or tumor-promoting phorbol esters (TPA). [6] [7] [8] [9] [10] PKC-mediated phosphorylation of threonine 654 (T654) inhibits EGFR TK activity 6, 8, [10] [11] [12] and consequently, reduces EGFR internalization and lysosomal degradation, as inactive EGFR is diverted to recycling endosomes for transport back to the cell surface. 13, 14 Pharmacological inhibitors with increased PKC isoform specificity, RNAi knockdown and co-immunoprecipitations suggest that the widely expressed PKCa isoform interacts and phosphorylates T654-EGFR in normal colon and intestinal epithelial cells, and also pancreatic and squamous carcinoma. 15, 16 Like other PKCs, PKCa is rapidly recruited to the plasma membrane upon activation of phospholipase C, subsequent production of diacylglycerol and elevation of Ca 2 þ . 17 Ca 2 þ binding increases the affinity of PKCa for phosphatidylserine, which is followed by diacylglycerol binding and conformational changes to allow substrate binding and phosphorylation. 18, 19 In addition, Receptors for activated C kinase (RACKs) and A-kinase-anchoring protein (AKAP) 79/150 act as compartment-and signal-organizing scaffolds to promote and control phosphorylation of PKC isozyme substrates. 18, 20, 21 Membrane-bound RACKs and AKAPs selectively bind a particular PKC isozyme only in the active conformation and similar to other scaffolds, their relative amounts and differential expression contribute to signal specificity.
AnxA6 in EGFR overexpressing A431 epidermoid carcinoma, EGFR overexpressing (BT20, MDA-MB-468) and estrogen receptor (ER)-negative breast cancer cell lines (BCCs) 35 and human breast carcinoma 40 suggest that cell transformation and cancer progression deplete cells of a scaffold that could downregulate oncogenic signaling.
In the absence of heterologous stimuli, PKCa-mediated EGFR T654 phosphorylation does not contribute to negative feedback mechanisms downregulating EGFR in cell culture models. 41, 42 Little is known if EGFR T654 phosphorylation occurs in cancers and since there is no direct correlation between PKCa levels and EGFR activation in various tumors, including breast cancers, this could suggest that other factors may determine a modulating role for PKCa in EGFR signaling. 43, 44 Indeed, in SCC12 human squamous carcinoma cells, CD82, caveolin-1 and ganglioside GM3 are required for PKCa-mediated EGFR T654 phosphosporylation. 16 Alternatively, members of the protein kinase N (PNK) family have recently been shown to contribute to basal, but not EGFstimulated, T654-EGFR phosphorylation. 45 Here, we demonstrate that AnxA6 is a scaffold for PKCa to promote EGFR T654 phosphorylation upon EGF stimulation, which is associated with reduced EGFR tyrosine phosphorylation, internalization and degradation. PKCa depletion restores EGFR tyrosine phosphorylation and cell growth in AnxA6 expressing A431 cells. AnxA6 levels modulate the ability of PKCa to interact with and downregulate ligand-induced EGFR signaling. AnxA6 interacts with both EGFR and PKCa and increases PKCa membrane association. Most strikingly, stable membrane anchoring of AnxA6 increases PKCa levels at the plasma membrane even in unstimulated cells. Altogether, these findings suggest that elevated AnxA6 levels facilitate PKCa-dependent negative feedback mechanisms to downregulate ligand-induced EGFR signaling.
RESULTS

AnxA6 inhibits EGFR tyrosine phosphorylation
AnxA6 has been co-purified with activated EGFR 37, 46 and promotes membrane association of PKCa. 29 To investigate if these observations could be linked to EGFR signaling, we compared EGFR tyrosine phosphorylation in EGFR immunoprecipitates from A431 cells, which express B1-3 Â 10 6 EGF receptors/cell, but lack endogenous AnxA6 (A431wt), and A431 stably expressing AnxA6 (A431-A6), 34, 35, 47 using an antiphosphotyrosine-specific antibody ( Figure 1A ). A431wt and A431-A6 cells express comparable amounts of EGFR, and EGF robustly stimulates EGFR tyrosine phosphorylation (pY-EGFR) in A431wt cells (compare lanes 1 and 2). In contrast, EGF-induced tyrosine phosphorylation of EGFR was reduced by 83 ± 8% in A431-A6 cells (lanes 3 and 4). Next, we analyzed EGFR activation in A431 cells±AnxA6 by immunofluorescence microscopy ( Figure 1B) . EGFR is predominantly localized at the cell surface in both cell lines ( Figure 1B , panels a and b) and concentrated in plasma membrane-enriched fractions upon fractionation using Percoll gradients (Supplementary Figure S1a) . In unstimulated cells, anti-phosphotyrosine (pY) staining at the cell surface of both cell lines was not detectable ( Figure 1B , panels c and d). Consistent with the results from EGFR immunoprecipitates, EGF-stimulated A431wt cells displayed a very strong anti-pY staining at the plasma membrane ( Figure 1B , panel e), while anti-pY staining remained almost undetectable in A431-A6 upon EGF stimulation (panel f).
To compare if Ca 2 þ elevation could downregulate pY-EGFR levels in A431wt and A431-A6 cells, A431wt and A431-A6 cells were preincubated ± Ca 2 þ -ionophore for 3 min to elevate cellular Ca 2 þ levels, followed by addition of EGF (10 ng/ml) for 5 min. Then, crude membranes were isolated by ultracentrifugation, and analyzed for the amounts of activated EGFR and Erk1/2 ( Figure 1C ). In A431wt, EGF stimulates EGFR tyrosine phosphorylation (compare lanes 1 and 2), and Ca 2 þ elevation further increased EGF-inducible pY-EGFR levels (compare lanes 2 and 4). In line with Figures 1A and B , EGF-induced pY-EGFR levels in A431-A6 cells were reduced 62 ± 10% ( Figure 1C , compare lanes 1-2 and 5-6). In contrast to A431wt cells, EGFR tyrosine phosphorylation of EGF-stimulated A431-A6 cells was completely abolished with ionomycin (compare lanes 3-4 and 7-8). Consistent with AnxA6 inhibiting EGFR effector pathways, 34, 35 possibly in a Ca 2 þ -dependent manner, Erk1/2 phosphorylation (PErk1/2) in A431-A6 cells was reduced ± ionomycin ( Figure 1C , compare lanes 1-2 and 5-6, 3-4 and 7-8).
We have previously demonstrated that AnxA6 potentiates the Ca 2 þ -dependent membrane targeting of PKCa in Chinese Hamster Ovary (CHO) cells. 29 Similarly, A431-A6 cells exhibited higher levels of membrane-associated PKCa ± EGF ( Figure 1C , compare lanes 1-2 with 5-6) and Ca 2 þ elevation compared with A431wt controls (compare lanes 3-4 with 7-8). The increased ratios of membrane-associated vs cytosolic PKCa in A431-A6 cells ± EGF support these findings (Supplementary Figure S1b) . As shown for EGFR overexpressing BCCs stably overexpressing AnxA6, 35 membranes from unstimulated and EGF-treated A431-A6 cells contain significant amounts of AnxA6 ( Figure 1C , lanes 5-8; Supplementary Figure S1b ). This might reflect substantial amounts of membrane-associated and Ca 2 þ -independent AnxA6 proteins described previously. 48 In addition, another pool of AnxA6 proteins is targeted to the membrane in a Ca 2 þ -dependent manner ( Figure 1C , lanes 7 and 8). Taken together, this suggested that AnxA6-induced PKCa membrane association might establish negative feedback loops upon EGF or Ca 2 þ activation that facilitate EGFR inhibition.
Annexin A6 promotes T654 phosphorylation of EGFR Based on AnxA6 reducing pY-EGFR levels, increasing PKCa membrane association (Figures 1A-C) and interacting with PKCa, 28, 29 we hypothesized that AnxA6 might increase T654-EGFR phosphorylation, possibly in an EGF-and PKCadependent manner, to inactivate EGFR. In fact, strong PKC stimuli, such as TPA, promote heterologous desensitization of EGFR, even in A431wt cells [6] [7] [8] [9] [10] 42 and consistent with these studies, TPA strongly inhibited EGF-inducible EGFR tyrosine phosphorylation in both A431wt and A431-A6 cells (Supplementary Figure S1c) .
To determine if elevated AnxA6 levels promote EGF-inducible T654-EGFR phosphorylation, EGFR immunoprecipitates from A431wt and A431-A6 cells that were analyzed for pY-EGFR (see Figure 1A ), were examined for pT654-EGFR levels and coprecipitation of AnxA6 and PKCa. Similarly to previous studies, 7, 41, 42 EGF induced minor EGFR T654 phosphorylation in A431wt (Figure 2A, lanes 1 and 2) , using an antibody specifically recognizing pT654-EGFR. In contrast, EGF-stimulated A431-A6 cells displayed much stronger phosphorylation of T654-EGFR (lanes 3 and 4). Kinetic studies in EGF-stimulated A431wt cells comparing the profiles of pY-and pT654-EFGR levels (t ¼ 0-30 min) revealed rapid downregulation of EGFR tyrosine phosphorylation, while pT654-EGFR levels remained low throughout the incubation period. In contrast, in A431-A6 cells, T654-EGFR phosphorylation peaked at t ¼ 5 min to return to basal levels thereafter (Supplementary Figure S1d) . At this time point (t ¼ 5 min), we observed increased pT654-EGFR staining at the plasma membrane of EGF-incubated A431-A6 cells (see arrows in Supplementary Figure S1e ), indicating that AnxA6-stimulated and PKCa-mediated EGFR inhibition occurs predominantly at the plasma membrane during early stages of EGFR signaling. AnxA6-induced upregulation of pT654-EGFR levels in A431 was not associated with 2) and A431-A6 cells (lanes 3 and 4) incubated ± EGF (10 ng/ml for 3 min) were immunoprecipitated with mouse monoclonal anti-EGFR and analyzed for tyrosine phosphorylation (pY-EGFR) and total EGFR by western blotting. Relative levels of activated EGFR in A431wt and A431-A6 from five independent experiments were quantified and normalized to total EGFR. The mean values (±s.e.m.) are shown (**Po0.01 for Student's t-test). (B) A431wt and A431-A6 cells were plated on coverslips, starved overnight, incubated ± 50 ng/ml EGF for 3 min, fixed and stained with anti-EGFR (EGFR, panels a and b), anti-phosphotyrosine (pY-EGFR) and 4,6-diamidino-2-phenylindole dihydrochloride (panels c-f ) as indicated. For comparison of the phosphotyrosine staining intensity in A431wt and A431-A6 cells, experiments were performed in parallel, and images were captured using identical contrast and exposure times. Bar is 10 mm. (C) Crude membranes from A431wt (lanes 1-4), A431-A6 (lanes 5-8), preincubated±ionomycin (2 mM for 3 min), followed by addition of EGF (10 ng/ml for 3 min), were analyzed by western blotting for tyrosine phosphorylated (pY-EGFR) and total EGFR, activated Erk1/2 (P-Erk1/2) and Total Erk1/2, PKCa, AnxA6, and Pan Ras as indicated. Relative levels of activated EGFR and membrane-bound PKCa in A431wt (white bars) and A431-A6 cells (black bars) from three independent experiments were quantified, normalized to total EGFR and Pan Ras, respectively. The mean values ( ± s.e.m.) are shown (**Po0.01 for Student's t-test). A431wt and A431-A6 cells were incubated ± 10 ng/ml EGF for 3 min, subjected to EGFR immunoprecipitation and analyzed for total EGFR, pT654-EGFR, AnxA6 and PKCa as indicated. The relative amounts of PKCa and AnxA6 ± EGF in the immunoprecipitates from two independent experiments were quantified and normalized to total EGFR. The mean values ( ± s.e.m.) are given. (B) A431wt and A431-A6 cells were transfected with untagged constitutively active PKCa (CAPKCa). Twenty-four hours after transfection, cells were starved overnight and incubated±10 ng/ml EGF for 3 min and subjected to EGFR immunoprecipitation as described above. Immunoprecipitates (IPs) and whole cell lysates (WCLs) were analyzed for total EGFR, pT654-EGFR, AnxA6, CA-and total PKCa as indicated. (C, D) COS-1 were grown on coverslips and co-transfected with AnxA6-CFP (C) or PKCa-CFP (D) (panels a and d) (green) and EGFR-YFP (panels b and e) (red). Twenty-four hours after transfection, cells were starved overnight and treated ± 100 ng/ml EGF for 3 min as indicated. Cells were fixed and analyzed by confocal microscopy. The merged images are shown (panels c and f ). Squares with regions of interest are shown as enlarged sections with arrows indicating colocalization of AnxA6 and PKCa with EGFR in EGF stimulated cells, respectively. Bar is 10 mm. (E) A431wt and A431-A6 cells with stable PKCa knockdown were incubated±10 ng/ml EGF for 3 min. Cells stably expressing scrambled RNAi served as control (lanes 1, 3 and 4). Cell lysates were subjected to EGFR immunoprecipitation and analyzed for tyrosine phosphorylated (pY-EGFR), pT654-and total EGFR. The amount of PKCa and actin in the WCL is shown. Relative pYand T654-EGFR phosphorylation of cells expressing scrambled RNAi (white bars) and RNAi targeting PKCa (black bars) from three independent experiments was quantified and normalized to total EGFR. The mean values ( ± s.e.m.) are given (*Po0.05 for Student's t-test). aberrant upregulation of PKCa or others PKC isoforms, as judged by western blot analysis using PKC isoform-specific antibodies (Supplementary Figure S1f) . Figure S1g) . Together with AnxA6 co-precipitating with EGFR in an EGF-inducible manner in A431-A6 cells (Figure 2A , lanes 3 and 4), these results indicate that AnxA6/EGFR interaction might increase the association of PKCa with EGFR.
To rule out limiting amounts of activated PKCa in A431wt cells, A431±AnxA6 were transfected with constitutively active PKCa (CA-PKCa), starved overnight, incubated±EGF and cell lysates were subjected to EGFR immunoprecipitations ( Figure 2B ). In favor of AnxA6 increasing EGFR/PKCa interaction, increased amounts of CA-PKCa co-immunoprecipitated with anti-EGFR in A431-A6 cells ± EGF compared with controls (compare lanes 1-2 with 3-4). As shown above (Figure 2A ), increased co-immunoprecipitation of PKCa with EGFR in A431-A6 cells correlated with upregulated basal and EGF-stimulated pT654-EGFR levels ( Figure 2B ).
To further characterize potential interaction of EGFR and AnxA6 in living cells, COS-1 cells were co-transfected with AnxA6-CFP and EGFR-YFP (yellow fluorescent protein), stimulated ± EGF, fixed and analyzed by confocal microscopy ( Figure 2C ). In unstimulated cells, AnxA6 is predominantly cytosolic 35, 49 and does not colocalize with EGFR (panels a-c, see also enlarged squares). In agreement with the biochemical data ( Figures 1 and 2 ), EGF and Ca 2 þ (not shown) stimulated translocation and colocalization of AnxA6-CFP with EGFR-YFP at the plasma membrane (panels d-f, see arrows in enlarged sections). Interestingly, colocalization of AnxA6 and EGFR appeared more prominent in structures that could resemble circular dorsal ruffles ('waves'), which are dynamic and transient actin-based protrusions on the cell surface that form in response to EGFR activation. 50 COS-1 cells co-transfected with PKCa-CFP and EGFR-YFP verified that PKCa is predominantly cytosolic in unstimulated cells and colocalizes with EGFR after EGF stimulation ( Figure 2D ).
Next, we aimed to determine EGFR tyrosine and T654 phosphorylation in A431-A6 cells upon PKC depletion. Therefore, A431-A6 cells were initially incubated overnight with phorbol esters, a common pharmacological approach to attenuate PKC isozyme expression. 29 This rendered PKCa expression almost undetectable, but restored basal and EGF-inducible EGFR tyrosine phosphorylation and strongly increased Erk1/2 activation (not shown). As prolonged TPA treatment also reduces expression of other PKC isoforms, 29, 51 we analyzed pY-EGFR levels in A431wt
and A431-A6 cell lines after stable PKCa knockdown using RNAi ( Figure 2E ). Loss of PKCa did not significantly alter pY-EGFR and pT654-EGFR levels in EGF-stimulated A431wt cells compared with RNAi control (lanes 1 and 2). In contrast, PKCa depletion in A431-A6 cells reduced T654-EGFR phosphorylation, which was associated with increased EGF-inducible EGFR tyrosine phosphorylation (compare lanes 3-4 with 5-6). Similar results were obtained with catalytically inactive and dominant-negative PKCa and the PKCa inhibitor Gö 6976 (data not shown).
PKCa depletion restores EGFR degradation in AnxA6 expressing A431 cells Increased T654-EGFR phosphorylation leads to reduced EGFR internalization and degradation. 13, 14 Based on the findings described above, we hypothesized decreased EGFR internalization and degradation in A431-A6 cells. To measure EGFR internalization, A431wt and A431-A6 were incubated with 125 I-EGF (5 ng/ml) for 5 min at 37 1C and cell surface-bound and internalized 125 I-EGF was determined as described. 52 Consistent with reduced EGFR activation, 125 I-EGF internalization was decreased in A431-A6 cells by 42±4% compared with A431wt ( Figure 3a) . Then, EGFR protein levels were monitored in A431wt and A431-A6 cells upon stimulation with 10 ng/ml EGF for 5-30 min (Figure 3b ). In EGF-treated A431wt cells, rapid EGFR degradation (33±3%) was evident after 15 min (control, top panel, lanes 1-3). In contrast, EGFR protein levels remained constant in A431-A6 over this time period (control, top panel, lanes 6-10), indicating slower EGFR degradation kinetics. In PKCdepleted A431wt cells (TPA ON), 24±6% EGFR degradation was detectable after 20 min (bottom panel, lanes 4 and 5). In line with the recovery of EGFR tyrosine phosphorylation after PKCa depletion ( Figure 2E ), 44-55% EGFR degradation occurred after 20-30 min EGF treatment in PKC-depleted A431-A6 cells (Figure 3b , TPA ON, bottom panel, lanes 9 and 10). Importantly, stable PKCa depletion effectively restored EGFR degradation kinetics in A431-A6 cells (Figure 3c , lanes 4-6), further pointing at AnxA6 levels not only determining EGFR activity, but also the intracellular fate of EGFR, in a PKCa-dependent manner.
PKCa knockdown restores cell growth in A431 cells expressing AnxA6 Given that PKCa depletion restored EGFR activation in A431-A6 cells ( Figure 2E ), we then compared clonogenic growth of A431wt and A431-A6 cell lines with stable PKCa knockdown (Figure 4a ). Cell lines stably expressing scrambled RNAi served as controls. As shown previously, 35 clonogenic growth of A431-A6 was reduced 47±6% compared with controls (**Po0.001). Stable PKCa knockdown slightly increased the number of colonies in A431wt cells, but most noticeably, significantly increased cell growth in A431-A6 cells (2.2±0.5-fold; **Po0.001). Likewise, colorimetric (MTT) proliferation assays confirmed 46±3% decreased cell 3 cells/well) and grown in DMEM, 0.1% FCS and 10 ng/ml EGF, observed twice weekly, fixed and stained as described in Materials and methods. A representative image from four independent experiments with triplicate samples is shown. Colonies containing more than B40 cells were quantified using ImageJ software. The number of colonies (±s.d.) is given (**Po0.01 for Student's t-test). (b) A431wt and A431-A6 cells ± stable PKCa knockdown were grown in 10% FCS for 72 h. Cell proliferation was monitored using an MTT assay. Mean values ± s.e.m. of five independent experiments with triplicate samples are given (**Po0.01 for Student's t-test, respectively). growth in A431-A6 cells (Figure 4b ; **Po0.01), which was significantly elevated upon stable PKCa knockdown (**Po0.01). These findings indicate that the inhibitory effect of AnxA6 on cell growth in A431-A6 cells involves PKCa-mediated EGFR inactivation.
T654 EGFR phosphorylation is coupled to EGFR TK activity To get mechanistic insights into AnxA6/PKCa-mediated EGFR inactivation, we investigated if T654-EGFR phosphorylation in A431-A6 cells could occur before and independent of EGFR tyrosine phosphorylation. Therefore, we next compared pY-and pT654-EGFR levels of EGFR immunoprecipitates from A431wt and A431-A6 cells preincubated with the EGFR TK inhibitor AG1478 (Figure 5a ). Consistent with the data shown above (Figures 1  and 2 ), A431-A6 cells are characterized by reduced pY-EGFR and increased pT654-EGFR levels (compare lanes 1-4). Most strikingly, preincubation with AG1478 not only blocked EGFR tyrosine-, but also T654 phosphorylation in both cell lines. Overnight exposures confirmed increased basal T654-EGFR phosphorylation in A431-A6 cells and revealed only residual pT654-EGFR phosphorylation in both A431wt and A431-A6 cells upon preincubation with AG1478 (not shown). Hence, these findings suggest that EGFR tyrosine phosphorylation is required to enhance subsequent T654-EGFR phosphorylation in A431-A6 cells.
To further address if AnxA6/PKCa-mediated T654-EGFR phosphorylation involves EGFR tyrosine phosphorylation, we analyzed immunoprecipitates using the phosphotyrosine and pT654-EGFRspecific antibodies (Figure 5b ). In line with reduced EGFR activation in A431-A6 cells, B2-fold less pY-EGFR was immunoprecipitated from A431-A6 cells as compared with A431wt cells (compare lanes 2 and 4). pY immunoprecipitates in both cell lines also show pT654-EGFR phosphorylation, indicating that activated EGF receptors become phosphorylated at the T654 residue. Similar to the findings described above (Figures 2A and B) , increased amounts of pT654-EGFR were immunoprecipitated from unstimulated and EGF-treated A431-A6 cells (Figure 5b , compare lanes 6-7 with 8-9). This pool of pT654-EGFR contained only residual amounts of phosphorylated tyrosines in both cell lines. These experiments do not fully establish a coupling of tyrosine and T654-EGFR phosphorylation in AnxA6 expressing cells and cannot discriminate if EGFR tyrosine phosphorylation is suppressed on the same EGF receptors that encounter T654 phosphorylation. Alternatively, tyrosine phosphorylation on some EGF receptors could still be responsible for increased recruitment of AnxA6/PKCa complexes to enhance subsequent T654 phosphorylation of all EGF receptors. However, these findings could indicate that EGFR tyrosine phosphorylation is followed by T654-EGFR phosphorylation. Subsequent dephosphorylation of tyrosine residues then leads to the accumulation of pT654-EGFR during EGFR inactivation.
To address if AnxA6-mediated EGFR inhibition could involve alternative pathways independent of the EGFR T654 residue, we compared the ability of AnxA6 to inhibit tyrosine phosphorylation of EGFR wild-type (WT-EGFR) and the EGFR T654A mutant (T654A-EGFR), which shows increased EGFR TK activity and cannot be inhibited by PKC.
14 To avoid interference with the high levels of endogenous EGFR in A431 cells, the comparison of WT and mutated EGFR ± AnxA6 was performed in CHO cells, which express very low/undetectable EGFR. 13, 14 CHOwt with low endogenous AnxA6, and the well-characterized AnxA6 expressing CHO-A6 cell line, 29, 49, 53, 54 were transfected with WT-EGFR and T654A-EGFR, and treated±100 ng/ml EGF for 3 min. Lysates were subjected to EGFR immunoprecipitation and analyzed for pY-and pT654-EGFR (Figure 5c ). Similar to previous data, EGF induces tyrosine phosphorylation of WT-EGFR in CHOwt, which is associated with weak pT654-EGFR levels (lanes 1 and 2) . Consistent with an increased TK activity, tyrosine phosphorylation of T654A-EGFR is already detectable in unstimulated CHOwt cells and further elevated with EGF (lanes 3 and 4) . In agreement with the results described above, CHO-A6 cells exhibit very low pY-and enhanced pT654 levels of WT-EGFR (Figure 5c , lanes 5 and 6). Most strikingly, tyrosine phosphorylation of the T654A-EGFR mutant in CHO-A6 cells (lanes 7 and 8) was comparable to CHOwt, with T654A-EGFR tyrosine phosphorylation being detectable in unstimulated CHO-A6 cells and further increasing with EGF (lanes 7 and 8). Although these data do not completely rule out alternative pathways of AnxA6-mediated EGFR inactivation, such as increased recruitment of tyrosine phosphatases, it is indicative of AnxA6 inhibiting EGFR via enhanced T654-EGFR phosphorylation, possibly in a PKCa-dependent manner.
Membrane-anchored AnxA6 is a docking site for PKCa Elevated AnxA6 levels promote PKCa membrane association ( Figure 1C; Supplementary Figure S1b ) and EGFR/PKCa interaction (Figures 2A and B) . Previous reports showed AnxA6/PKCa interaction 28, 29 and together with PKC scaffolds (RACKs, AKAP75/ 150, caveolin-1) recruiting PKC isoforms to membranes, 16, 20, 21 we hypothesized that membrane-bound AnxA6 could serve as a docking site for PKCa, possibly even in unstimulated cells. To address this question, and to avoid high endogenous EGFR levels in A431 interfering with PKCa localization studies, we first analyzed PKCa membrane association biochemically in HEK293 cells, which express only residual amounts of EGFR. 55 Therefore, membranes from control and HEK293 stably expressing AnxA6 fused to YFP and the membrane targeting sequence of K-Ras (AnxA6-YFP-tK) 56 were analyzed for PKCa membrane association. In HEK293 control cells stably expressing mCherry-tK, EGFinducible membrane recruitment of endogenous AnxA6, PKCa and p120GAP was evident ( Figure 6A, lanes 1 and 2) . In contrast, elevated amounts of both membrane-bound PKCa and p120GAP in unstimulated HEK293 cells expressing membrane-tagged Anx6-YFP-tK (lane 3) were observed. Similar results were obtained from HEK293 stably expressing AnxA6 fused to the lipid anchor of H-Ras (Monastyrskaya et al.;
56 data not shown). Increased membrane targeting of PKCa in HEK293 cells expressing membrane-anchored AnxA6 (Anx6-YFP-tK) correlated with reduced tyrosine phosphorylation of EGFR, (pY-EGFR) and MAPK (P-Erk1/2) activation and a detectable increase in T654-EGFR phosphorylation in the presence of EGF ( Figure 6B ), altogether suggesting constitutive interaction of membrane-anchored AnxA6 and PKCa.
To confirm increased PKCa membrane association in cells expressing membrane-anchored AnxA6 in living cells, even in the absence of Ca 2 þ , we first analyzed mCherry-PKCa localization ± GFP-AnxA6-tK by fluorescence microscopy in HEK293 cells. However, similar to the biochemical analysis ( Figure 6A, lane 1) , mCherry-PKCa membrane association was already observed in unstimulated HEK293 cells not expressing membrane-anchored AnxA6. We therefore utilized an AnxA6-depleted HeLa cell line (HeLa-A6KD) described recently, 57 which express only B1.5 Â 10 5 EGF receptors/cell 5 for further imaging studies. Cells were transfected with mCherry-PKCa and GFP-tK or GFP-AnxA6-tK, respectively ( Figure 6C ), starved overnight, incubated±the Ca 2 þ -chelator BAPTA-AM, fixed and analyzed by fluorescence microscopy. Regardless of treatment, mCherry-PKCa was predominantly localized in the cytosol of GFP-tK expressing cells (panels a-f). In contrast, substantial amounts of mCherry-PKCa were localized at the plasma membrane in cells expressing membraneanchored AnxA6, even after incubation with BAPTA-AM (see arrows in panels g-l).
The above findings suggested that the scaffolding function of membrane-anchored AnxA6 for PKCa might involve direct and Ca 2 þ -independent interaction. To address if constitutive interaction of endogenous AnxA6 and PKCa can occur, HeLa-A6KD and HeLa WT cells, which contain substantial amounts of AnxA6 and 2 and 5-6 ) and A431-A6 cells (lanes 3-4 and 7-8) preincubated ± AG1478 (10 mM for 60 min), followed by addition of EGF (10 ng/ml for 3 min), were immunoprecipitated with anti-EGFR and analyzed for tyrosine phosphorylation (pY-EGFR), pT654-EGFR and total EGFR by western blotting. Relative pY-EGFR and pT654-EGFR levels in A431wt and A431-A6 from two independent experiments were quantified and normalized to total EGFR. The mean values ( ± s.e.m.) are shown. (b) Cell lysates from A431wt (lanes 1 and 2) and A431-A6 cells (lanes 3 and 4) incubated ± EGF (10 ng/ml for 3 min) were immunoprecipitated with anti-pY (lanes 1-5) or anti-pT654-EGFR (lanes 6-10) and analyzed for pY-, pT654-by western blotting. Relative pY-EGFR and pT654-EGFR levels in A431wt and A431-A6 from two independent experiments were quantified. The mean values ( ± s.e.m.) are shown. (c) CHOwt and CHO-A6 cells were transfected with YFP-tagged WT EGFR and the T654A EGFR mutant (T654A). Twenty-four hours after transfection, cells were starved overnight and incubated±100 ng/ml EGF for 3 min as indicated. Cell lysates were subjected to EGFR immunoprecipitation and analyzed for tyrosine (pY-EGFR) and T654-EGFR phosphorylation (pT654-EGFR). The amount of total EGFR in the immunoprecipitate and PKCa and AnxA6 in the cell lysate is shown. Two different blots for PKCa and EGFR, respectively, were joined together in this presentation. The relative pY-EGFR phosphorylation of WT-EGFR (white bars) and T654A-EGFR from three independent experiments was quantified and normalized to total EGFR. The mean values ( ± s.e.m.) are given (*Po0.05 for Student's t-test). 1 and 2) and AnxA6-YFP-tK cells (A6-YFP-tK, lanes 3 and 4) were incubated±EGF (100 ng/ml) for 5 min. Crude membranes were isolated and analyzed by western blotting for (A) PKCa, p120GAP, AnxA6-YFP-tK, AnxA6, Pan-Ras and (B) activated EGFR and Erk1/2 (pY-EGFR, P-Erk1/2), pT654-EGFR, total EGFR and total Erk1/2 as indicated. (C) HeLa-A6KD cells were grown on coverslips and co-transfected with mCherry-PKCa (red) and GFPtK (a-f ) or AnxA6-GFP-tK (g-l, green). Twenty-four hours after transfection, cells were starved overnight, incubated ± 10 mM BAPTA-AM for 30 min, fixed and analyzed by fluorescence microscopy. The merged images are shown (panels c, f, i and l). Arrows indicate membrane localization of mCherry-PKCa in AnxA6-GFP-tK expressing cells. Bar is 10 mm. Figure S2a) , were compared. Similar amounts of AnxA6 were found in PKCa immunocomplexes from control and EGF-stimulated HeLa WT cells (Supplementary Figure  S2b, lanes 1 and 2) . Vice versa, PKCa was present in AnxA6 immunoprecipitates from control and EGF-stimulated HeLa WT cells (lanes 1 and 2), indicating that AnxA6 and PKCa can interact constitutively. In support of this interaction contributing to EGFR inactivation, we observed increased pY-EGFR and loss of both EGF-inducible pT654 EGFR phosphorylation and PKCa co-immunoprecipitation with EGFR in HeLa-A6KD cells (Supplementary Figure 2c) .
PKCa and show reduced T654-EGFR phosphorylation upon PKCa depletion (Supplementary
AnxA6 levels modulate EGFR activation in EGFR overexpressing head and neck cancer cells AnxA6 promotes PKCa-mediated EGFR inactivation in A431-A6 cells (Figures 1-5 ). To identify if AnxA6 levels modulates pT654-and pY-EGFR levels in other cell models with de-regulated EGFR, we compared EGFR overexpressing head and neck cancer cell lines (HNSCCs) Fadu and Detroit 562 (Figure 7a) . Indeed, these cell lines displayed a pattern of T654-EGFR phosphorylation that was not linked to PKCa amounts, but to high and low levels of endogenous AnxA6, respectively (compare lanes 1-2 and 3-4).
We next transiently transfected Fadu and Detroit 562 with AnxA6 and determined pY-and pT654 EGFR levels±EGF (Figure 7b ). In both HNSCC lines, overexpression of AnxA6 decreased EGF-induced EGFR tyrosine phosphorylation, while pT654-EGFR levels were increased (Figure 7b , compare lanes 2, 4, 6 and 8). As shown for A431, Erk1/2 activation was strongly reduced in both Fadu and Detriot 562 ectopically expressing AnxA6 (Figure 7b) . Supporting an involvement of PKCa in EGFR signaling in HNSCC, PKCa depletion (B70-80%) in Fadu cells correlated with B50% reduced T654-EGFR phosphorylation without affecting expression of other PKC isoforms (Supplementary Figure S2a) . Similarly, stable AnxA6 overexpression in EGFR overexpressing BCCs (MDA-MB-468, BT20; 35) reduced pY-EGFR, elevated pT654-EGFR levels and increased PKCa membrane association (Supplementary Figures S3a-c) . Hence, AnxA6 levels modulate EGFR activity and PKCa localization in various EGFRrelated cancer cell models. Interestingly, the various EGFR overexpression models (A431, HNSCC, BCCs; compare Figures 2A  and 7a, Supplementary Figure S3b) and other model systems (HeLa, HEK293; see Figure 6B and Supplementary Figure S2 ) display fundamental differences in respect to the magnitude of basal and ligand-induced T654-EGFR phosphorylation with and without AnxA6. Taken together, this suggests that besides AnxA6 promoting PKCa/EGFR complex formation, multiple coexisting models of PKCa-mediated EGFR attenuation may exist which probably contribute differently to EGFR inactivation in the different cell lines. 16, 45 Little is known if T654-EGFR phosphorylation occurs in cancers. To get an initial insight if T654-EGFR phosphorylation possibly correlates with PKCa levels or other factors, we prepared lysates from grade 3 carcinomas (n ¼ 8 per group) from luminal (ER þ , progesterone receptor (PR) þ , Her2 À ), Her2-positive (ER À , PR À ) and basal (triple negative; ER À , PR À , Her2 À ) breast cancers. Western blotting revealed very low EGFR levels in six out of eight luminal cancers, and we therefore focused on Her2-positive and basal breast cancers, as EGFR amplification and de-regulation occurs and T654-EGFR phosphorylation was more likely to be detectable. Tissue samples were analyzed by western blotting for pT654-EGFR, total EGFR, PKCa, AnxA6, caveolin-1 and b-actin Figure 7 . AnxA6 inhibits EGFR activation in EGFR overexpressing head and neck cancer cells. (a) Fadu and Detroit 562 were starved overnight, and incubated with 10 ng/ml EGF for 3 min as indicated. Cell lysates were analyzed for the amount of total and T654-phosphorylated EGFR (pT654-EGFR), PKCa and AnxA6. The amount of pT654-EGFR phosphorylation from three independent experiments was quantified and normalized to total EGFR. The mean values ( ± s.e.m.) are shown (**Po0.01 for Student's t-test). (b) Fadu and Detroit 562 were transfected with AnxA6, starved overnight and incubated ± 10 ng/ml EGF for 3 min as indicated. Cell lysates were analyzed for T654-EGFR phosphorylation (pT654-EGFR), total EGFR, PKCa, activated and total Erk1/2 and AnxA6. Crude membranes from duplicate samples were analyzed for EGFR tyrosine phosphorylation (pY-EGFR). The amount of pY-and pT654-EGFR phosphorylation from two independent experiments was quantified and normalized to total EGFR. The mean values (±s.e.m.) are given.
(Supplementary Figure S4) . High EGFR expression levels were observed and varied 5-to 8-fold in Her2-positive and basal carcinoma, respectively. Remarkably, T654-EGFR phosphorylation was detectable in most of these human cancer biopsies. In several Her2-positive (tissue sample #2, #3 and #10) and basal carcinomas (#8, #13 and #16), significant amounts of pT654-EGFR were associated with high EGFR levels. Supporting previous data that PKCa levels do not correlate with EGFR activity/phosphorylation, 43, 44 an elevated ratio of pT654-EGFR/EGFR was not associated with high PKCa levels (for example, #4, #13 and #16). Differential expression of AnxA6 and caveolin-1, which also promotes PKCamediated T654-EGFR phosphorylation, 16 was observed, with several samples exhibiting high pT654EGFR/EGFR ratios showing either high AnxA6 or caveolin-1 levels (#4, #5, #13 and #16). Although we were unable to observe a direct correlation between AnxA6 and pT654-EGFR levels, the heterogeneous and complex molecular entities of breast cancer subtypes might only identify correlations of AnxA6 levels with pT654-EGFR levels within small groups of certain subtypes and would require correlation studies using larger cohorts.
DISCUSSION
Here, we demonstrate that AnxA6 is a scaffold for PKCa establishing a negative feedback mechanism to downregulate ligand-induced EGFR signaling. Elevated AnxA6 levels enhance the ability of PKCa to phosphorylate T654-EGFR, which is associated with reduced EGFR tyrosine phosphorylation, internalization and degradation. AnxA6 promotes PKCa membrane targeting and PKCa/EGFR complex formation, possibly via direct interaction with both PKCa and EGFR. On the other hand, PKCa knockdown restores EGFR activation and clonogenic growth in AnxA6 expressing cells. Similarly, AnxA6 depletion increases pY-EGFR levels and reduces PKCa/EGFR interaction. Hence, the tumor suppressor activity of AnxA6 may include its ability to promote ligand-induced EGFR downregulation through increased membrane targeting of PKCa followed by EGFR/ PKCa complex formation and EGFR T654 phosphorylation.
In A431, which lack endogenous AnxA6, 34, 47 and other cell types, TPA-induced and PKC-mediated phosphorylation of T654-EGFR facilitates heterologous desensitization of EGF-induced EGFR signaling. 7, 14 Weak T654-EGFR phosphorylation in EGF-stimulated A431 cells 41, 42 made PKC an unlikely candidate to downregulate ligand-induced EGFR. Similar results were obtained in all cell lines with low AnxA6 levels in our study, including A431. Otherwise, PKC-related PNK kinases have recently been identified to facilitate constitutive T654-EGFR phosphorylation in A431wt cells, though these kinases appear to have little influence on pT654-EGFR levels in response to EGF. 45 However, Wang et al. 16 identified that caveolin-1 (cav-1), tetraspanin CD82 and ganglioside GM3 enabled association of EGFR with PKCa in EGF-stimulated SCC12 squamous carcinoma cells, to inhibit EGFR signaling. Some of these interactions seem cell specific and probably require GM3, CD82 and cav-1 to act as membrane organizers and stabilize the interaction of EGFR and PKCa in cholesterol-rich microdomains. 16 Alternatively, our findings suggest that AnxA6 levels determine the role of PKCa for ligand-induced EGFR downregulation in EGFR overexpressing A431, HNSCCs and BCCs, but also HeLa and HEK293 with low to moderate EGFR levels. Mechanistically, this could involve cytosolic and membrane-bound pools of AnxA6 constitutively binding to PKCa. Ca 2 þ elevation upon EGFR activation would further increase the recruitment of AnxA6 and PKCa into close proximity of EGFR. The ability of AnxA6 to interact with both PKCa and EGFR may increase the affinity of PKCa for EGFR, and establish a microenvironment promoting EGF-inducible PKCa/EGFR interaction, followed by T654-EGFR phosphorylation.
Interestingly, we recently discovered that high AnxA6 levels inhibit the exit of caveolin from the Golgi, decreasing the number of caveolae at the cell surface. 49, 54 While EGFR inactivation via CD82/GM3/cav-1-dependent mechanisms is likely to occur in cholesterol-rich membrane domains, 16 AnxA6 translocates to both cholesterol-rich and -poor membrane domains. 39 Fusion of AnxA6 to membrane anchors of K-and H-Ras both increased PKCa recruitment and reduced EGFR activity. K-and H-Ras anchors (tK, tH) can target heterologous proteins (for example, GFP) to cholesterol-poor and -rich microdomains, 58 yet the A6-tK and A6-tH fusion proteins were not exclusively found in these microdomains in subcellular fractionations (data not shown), indicating that the Ca 2 þ , phospholipid and cholesterol binding ability of AnxA6 contributes to membrane microlocalization. However, one can envisage that fine-tuning of AnxA6 and cav-1 expression and microlocalization might downregulate different EGFR effector pathways, as recruitment of PKCa via AnxA6 or CD82/GM3/cav-1 could target dissimilar pools of activated EGFR in different microdomains at the cell surface.
The spatio-temporal targeting of PKC isozymes to unique subcellular localizations is complex and involves diacylglycerol, Ca 2 þ , lipid binding through their C1 and C2 domains and scaffold proteins. 18, 19, 21 The PKC scaffolds RACK and AKAP79/150 are membrane associated and only recruit activated PKC isozymes. AKAP79/150 interacts with multiple PKC isozymes, 59 ,60 RACK1 and RACK2 selectively bind PKCb and PKCe via their C2 domains, respectively. 18, 21 Likewise, AnxA5 binds to the C2 domain of PKCd, 25 but AnxA5/PKCd assembly precedes PKCd membrane translocation and function. Similarly, AnxA6 (i) constitutively interacts with PKCa, (ii) increases PKCa membrane association and (iii) serves as a PKCa membrane docking site even in unstimulated cells. The AnxA6 linker, which separates AnxA6 annexin repeats 1-4 from 5-8, contains a PKC phosphorylation site at T356 61 and constitutively binds to C2 domains of other proteins, such as p120GAP. [33] [34] [35] In addition, we showed that a deletion mutant lacking the AnxA6 linker region and C-terminal Anx repeats cannot promote PKCa membrane recruitment. 29 Consistent with these findings, overexpression of this mutant in A431 cells did not promote T654-EGFR phosphorylation or EGFR/ PKCa complex formation. Therefore, the C2 domain of PKCa might be critical for membrane association not only through Ca 2 þ sensing and phospholipid binding, but also via a unique AnxA6/PKCa interaction. Alternatively, Kirsch and coworkers recently mapped the AnxA6/PKCa interaction within the AnxA6 C-terminus. 62 Hence, AnxA5 and AnxA6 may represent a new class of PKC scaffolds that can interact with PKC isozymes before cell activation, possibly ensuring rapid and site-specific membrane targeting of PKC isozymes from the cytosol upon activation.
We previously demonstrated that AnxA6 interacts with p120GAP and active H-Ras to promote p120GAP/H-Ras assembly and Ras/MAPK inhibition in EGFR overexpressing A431 and BCCs. 34, 35, 38 In addition, AnxA6 can interact with PKCa and EGFR to downregulate EGFR activation. Together with AnxA6 co-purifying with Raf-1, 36 the scaffolding function of AnxA6 may involve multiple protein-protein interactions and the recruitment of at least two regulators, p120GAP and PKCa, to EGFR and Ras. Several other EGFR/Ras/MAPK scaffolds also have multiple interaction partners. IQGAP1 binds to EGFR, B-Raf, Mek/Erk kinases and is required for maximal MAPK activation. 32 Kinase Suppressor of Ras binds to C-Raf, Mek1/2, Erk1/2 and Kinase Suppressor of Ras levels determine the magnitude of MAPK activation. 31 High amounts of AnxA6 might enable multiple, possibly simultaneous, interactions with different members of the EGFR/Ras/MAPK pathway to ensure signal termination. Differential expression, localization and recruitment of scaffolds that either stabilize or terminate EGFR/Ras/MAPK signaling could thereby integrate diverse signaling pathways and multiple cellular activities. Expression analysis of Her2-positive and basal breast carcinoma did not reveal an association between T654-EGFR phosphorylation and PKCa levels, confirming previous studies 43 , 44 and further indicating that scaffolds, such as AnxA6 and caveolin-1, 16 or even other kinases, 45 may contribute to EGFR inactivation. AnxA6 is downregulated in EGFR overexpressing and ER-negative BCCs. In these cells, elevation of AnxA6 reduced cell growth, whereas AnxA6 depletion increased transformation efficiency. 35 Decreased AnxA6 levels in human breast carcinoma, 40 and reduced growth of A431 cells ectopically expressing AnxA6 in mouse xenografts, 63 further suggest tumor suppressor activity of AnxA6 in cells with de-regulated EGFR and elevated WT (hyperactive) Ras activity. The ability of AnxA6 to promote PKCa-dependent EGFR inactivation in EGFR overexpressing A431, BCCs and HNSCC supports anti-proliferative properties of AnxA6 in certain susceptible cell types and co-operating genetic lesions, such as EGFR overexpression. Loss of 5q31-35, which contains the AnxA6 locus, is common in ER-negative breast tumors that carry ErbB2 gene amplifications, which have strong oncogenic potential. 64, 65 Deletion of 5q31-32, which contains around 40 genes, some of those, including AnxA6, with tumor suppressor properties, 66 is also associated with the myelodysplastic syndrome and acute myelogenous leukemia. It should also be noted that alternative splicing gives rise to two AnxA6 isoforms. While full-length AnxA6-1 is the predominant isoform in most tissues, increased levels of the shorter AnxA6-2 isoform lacking 524-VAAEIL-529 were found in some immortalized cell lines. It is unclear if the two isoforms fulfill different roles in tumorigenesis, but recent studies indicate different localization and regulation of AnxA6 isoforms. 67, 68 Alternatively, AnxA6 promoter methylation in A431wt and MDA-MB-468 35 suggests that enhanced EGFR and Ras/MAPK signaling might downregulate AnxA6 through epigenetic silencing.
Upregulation of PKCa has long been implicated in ER-negative breast cancers. 44, 68, 69 Consistent with published data, 70,71 we observed very low PKCa levels in a panel of ER-positive BCCs, while the majority of ER-negative BCCs contained significant amounts of PKCa (data not shown). Interestingly, ER-positive BCCs express substantial amounts of AnxA6, but most ER-negative BCCs express low to modest amounts of AnxA6, 35 indicating that loss of AnxA6 enables PKCa to target substrates other than EGFR, possibly leading to oncogenic signaling events.
Increasing evidence suggests that scaffold proteins regulating PKC isozyme localization provide exciting opportunities for therapeutic intervention. Peptides interfering with the interaction of PKC isoforms and their respective scaffolds can inhibit PKC membrane targeting and activity in cells and animal models of human disease. 21, 25 Recently, a short and PKCa-specific peptide inhibitor (QLVIAN) with similarities to the AnxA6 linker between Pos. 341 and 346 (ELSAVA), reduced breast cancer metastasis, but not primary tumor growth in mice. 44 Similar approaches will provide opportunities to investigate if tumor suppressor activity of AnxA6 in EGFR overexpressing cells is mediated via the potential scaffolding function of the AnxA6 linker region.
MATERIALS AND METHODS
Reagents and antibodies
DMEM, DMEM/F12, RPMI-1640, Ham's F-12, trypsin, L-glutamine, penicillin, streptomycin, Percoll and 4,6-diamidino-2-phenylindole dihydrochloride were from Invitrogen (Mulgrave, Victoria, Australia). Geneticin (G418), Mowiol and human recombinant EGF were from Merck (Frenchs Forest, NSW, Australia). BAPTA-AM, Ionomycin, 2-mercaptoethanol, 12-O-tetradecanoyl-phorbol-13-acetate (TPA), paraformaldehyde, Insulin, Gö 6976, AG1478 and sucrose were from Sigma (Caste Hill, NSW, Australia).
125 I-EGF and Protein G sepharose were from GE Healthcare (Chalfont, St Giles, UK). Mono-and polyclonal antibodies against EGFR, rabbit anti-pT654-EGFR were from Santa Cruz (Santa Cruz, CA, USA). Mouse monoclonal antibodies against PKCa, PKCb, PKCd, PKCe and PKCi, Pan Ras, p120GAP, and rabbit anti-caveolin were from BD Transduction Laboratories (Lexington, KY, USA). Antibodies against phosphotyrosine (mouse), activated Erk1/2 (P-Erk1/2; mouse), Total Erk1/2 (rabbit) and b-actin (rabbit) were from Cell Signalling (Beverly, MA, USA). The rabbit anti-AnxA6 antibody was prepared in our laboratory. 48, 53 Expression vectors encoding EGFP-AnxA6, AnxA6-CFP, and EGFP-or YFP-AnxA6±the lipid anchors of H-and K-Ras (AnxA6-YFP-tK, AnxA6-YFP-tH, AnxA6-EGFPtK) have been described. 35, 53, 56 The plasmid expressing inactive PKCa (DNPKCa) contains the bovine PKCa cDNA mutated at codon 368 from AAG (L) to AGA (R). 29 The constitutively active PKCa mutant (CA-PKCa) is a pseudosubstrate site deletion in the bovine PKCa cDNA removing codons 22-28 (RLGALRQ). Mutant and WT PKCa PCR fragments were cloned into pCRblunt (Invitrogen) and sequenced. For mCherry-PKCa, the cDNA was cloned into pEGFP-C1, where EGFP was replaced with mCherry. For CFPtagged PKCa, the human PKCa cDNA was cloned into pCFP-C1. Plasmids encoding GFP-tH, GFP-tK, EGFP-EGFR, YFP-EGFR and YFP-T654A-EGFR were kindly provided by J Hancock (Dallas, USA) and A Sorkin (Pittsburgh, USA), respectively. Cy3-and Cy5-conjugated secondary antibodies were from Molecular Probes (Eugene, OR, USA) and Jackson ImmunoResearch (Westgrove, PA, USA). Horseradish Peroxidase-labeled antibodies and SDS-PAGE molecular weight markers were from Cell Signalling. The breast cancer samples used in this study were provided by the Victorian Cancer Biobank, which is supported by the Victorian Government. The project was approved by the St Vincent's Hospital Sydney human research ethics committee (approval number HREC 08/145). All breast cancer samples were grade 3 carcinoma and classified by immunohistochemistry as luminal (ER þ , PR þ , Her2 À ), Her2-positive (ER À , PR À ) and basal (triple negative: ER À , PR À , Her2 À ).
Cell culture
A431wt, A431-A6, HeLa, HeLa-A6KD, COS-1 and HEK293 were grown in DMEM, Fadu and Detroit 562 in DMEM/F12, CHOwt and CHO-A6 in Ham's F12, together with 10% fetal calf serum (FCS), L-glutamine (2 mM), penicillin (100 U/ml) and streptomycin (100 mg/ml) at 37 1C, 5% CO 2 . MDA-MB-468, BT20 were grown in RPMI-1640 together with Insulin (0.3 U/ml) and FCS, glutamine, penicillin and streptomycin as above. For the generation of stable A431 cells expressing the AnxA6 mutant A6 1-175 , A431wt cells were transfected with pcDNAAnx6 and selected in the presence of 1 mg/ml G418 as described. 35, 53 After 2 weeks G418-resistant and A6 1-175 expressing colonies were identified. The generation of A431, MDA-MB-468, BT20 and CHO cell lines stably expressing AnxA6 and HEK293 stably expressing Anx6-YFP-tK has been described. [34] [35] [36] 53, 56 Suppression of PKCa and AnxA6 expression by RNAi 
Growth assays
Colony forming assays were performed as described. 72 Cells were fixed and stained with Diff Quick stain (Lab Aids, Australia). Images were captured using a Leica DMI3000B microscope (Leica Microsystems, North Ryde, NSW, Australia). Colonies with 440 cells were quantified using ImageJ (version 1.42; NIH, Bethesda, MA, USA) particle analysis mode.
Cell proliferation was determined using a colorimetric (MTT; 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay according to manufacturer's instructions. Cells (2 Â 10 3 , in triplicate) were grown in 10% FCS for 72 h. Cells were incubated with 20 ml of MTT (5 mg/ml) for 60 min, the media was removed and spectrophotometric absorbance of samples in dimethyl sulfoxide was measured at 550 nm (Microplate Reader, Model 689, Bio-Rad, Hercules, CA, USA) with a reference filter of 655 nm. All experiments were performed in triplicate in at least three separate experiments.
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Subcellular fractionation
Crude membranes from cells were prepared as described previously. 35, 73 In brief, cells lysed in 10 mM Tris-HCl (pH 7.5), 5 mM MgCl 2 , 1 mM EGTA, 1 mM DTT and protease inhibitors were homogenized and nuclei were removed by low speed centrifugation. Postnuclear supernatants were spun at 100 000 g at 4 1C for 30 min and membrane pellets were resuspended by sonication in 50 ml of lysis buffer. Aliquots were analyzed by western blotting for total and phosphorylated EGFR, PKCa, p120GAP, Ras and AnxA6.
Plasma membrane-enriched fractions were isolated from Percoll gradients as described. 34 In all, 1 Â 10 7 cells were washed in 0.25 M sucrose, 1 mM EDTA, 20 mM Tris-HCl, pH 7.8 plus protease inhibitors, collected and centrifuged. The postnuclear supernatant was layered on top of 8 ml of 30% Percoll and centrifuged at 84 000 g for 30 min in a Beckman 70.1 TI rotor (Gladesville, NSW, Australia). In all, 1 ml fractions from top to bottom were collected (plasma membrane in fractions 3-5), concentrated and analyzed for the amount of EGFR and Ras.
Internalization of 125 I-EGF
The internalization of 125 I-radiolabeled EGF was measured as described previously. 52 In all, 1 Â 10 6 cells were incubated with 1 ng/ml 
Immunoprecipitation
Immunoprecipitations were performed as described. 35, 74 In all, 1 Â 10 7 cells were starved overnight, washed twice in phosphate-buffered saline and scraped in 0.5 ml of lysis buffer (20 mM HEPES pH 7.2, 1% NP-40, 10% Glycerol (v/v), 50 mM NaF, 1 mM PMSF, 1 mM Na 3 VO 4 , 10 mg/ml leupeptin and 2 mg/ml aprotinin). The protein content was determined and 800-1000 mg of cell lysate was incubated with 2 mg of anti-EGFR (mouse), anti-phosphotyrosine (mouse), anti-pT654-EGFR (rabbit), anti-PKCa (mouse), anti-AnxA6 (rabbit), or control mouse/rabbit antibody overnight at 4 1C. Samples were added to Protein G sepharose and incubated for 2 h at 4 1C, centrifuged and washed four times in lysis buffer. The immunoprecipitates were analyzed for EGFR, pY-EGFR, pT654-EGFR, PKCa and AnxA6.
Immunofluorescence
Cells were seeded at 1 Â 10 5 /ml and grown on coverslips. In some experiments, cells were transfected with plasmids encoding AnxA6, PKCa or EGFR with Lipofectamine as described above. Twenty-four hours after transfection, cells were starved overnight and incubated with 10 mM BAPTA-AM for 30 min, or activated with EGF (10-100 ng/ml) or ionomycin (2 mM) for 3 min, washed with cold phosphate-buffered saline and fixed with 4% paraformaldehyde (or methanol for anti-pT654-EGFR). Cells were washed, permeabilized with 0.1% saponin and incubated with first and secondary antibodies as described. 49, 54 EGFR, pT654-EGFR and phosphotyrosine were visualized using mouse anti-EGFR, rabbit antipT654-EGFR and mouse anti-phosphotyrosine as first and Cy3-and Cy5-donkey anti-mouse or rabbit (Cy3) as secondary antibodies (Jackson ImmunoResearch). Samples were washed extensively and coverslips were mounted with Mowiol (Merck). Localization of EGFR, PKCa and AnxA6 was studied using a Leica DMI3000B inverted fluorescent microscope and images were collected with IPLab Gel software (Leica Microsystems). In some experiments, images were analyzed with a Leica TCS SP5 laser scanning confocal microscope (Leica Microsystems, Heidelberg, Germany) equipped with an APO Â 63 oil immersion objective lens. Image analysis and manipulation was performed with ImageJ NIH image software (NIH).
Western blot analysis
Cell and tissue lysates and samples from immunoprecipitations and membrane preparations were separated by 8-12.5% SDS-PAGE and transferred onto Immobilon-P (Millipore, Billerica, MA, USA). Proteins were detected using their specific primary antibodies, followed by horseradish peroxidase-conjugated secondary antibodies and enhanced chemiluminescence detection (ECL, Perkin-Elmer, Glen Waverly, Victoria, Australia).
